Drug reference

Nivolumab

Monoclonal Antibody · Antineoplastic

Monoclonal AntibodyAntineoplastic

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

3 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 4 →

LenalidomideSevereDatabaseDDInter
PomalidomideSevereDatabaseDDInter
ThalidomideSevereDatabaseDDInter

Mechanism

Nivolumab is an immune checkpoint inhibitor. It can induce autoimmune thyroid disease.

Indications

Melanoma (in combination with ipilimumab) (specialist use only)Advanced renal cell carcinoma (in combination with ipilimumab) (specialist use only)Metastatic melanomaNon–small cell lung cancerRenal cell carcinomaHead and neck cancers (clinical trials)Breast cancer (clinical trials)Small cell lung cancer (clinical trials)Hodgkin lymphoma (clinical trials)Gastric cancer (clinical trials)Hepatocellular carcinoma (clinical trials)Bladder cancer (clinical trials)Ovarian cancer (clinical trials)Colon cancer (clinical trials)Merkel cell carcinoma (clinical trials)cancer therapyadvanced or resected high-risk melanomapreviously treated advanced NSCLCRCCadvanced head and neck cancerMSI-H or mismatch repair–deficient colorectal cancerhepatocellular carcinomarelapsed/refractory classical Hodgkin lymphomaadvanced melanomaadjuvant anti-PD-1 immunotherapy for stage IIB or IIC melanomaadjuvant systemic therapy for stage III and stage IV melanomafirst-line treatment of advanced melanoma in combination with relatlimabRelapsed Hodgkin's Lymphoma (in combination with brentuximab or ICE chemotherapy for salvage therapy)Upfront treatment of advanced-stage classical Hodgkin's Lymphoma (in combination with AVD chemotherapy)

Dosing

Adult: Consult product literature for combination therapy with ipilimumab for Melanoma or Advanced renal cell carcinoma.

Pharmacokinetics

Half-life

26.7 days

Side effects

Common

rashfatiguedyspneamusculoskeletal paindecreased appetitecoughnauseaconstipationskin rashdiarrhea (sometimes severe, life-threatening colitis)

Serious

Autoimmune thyroid disease (hypothyroidism or hyperthyroidism)
Immune-related adverse events (hepatitis, pneumonitis, colitis, rash, vitiligo, endocrine pathology)
immune-mediated pneumonitis
colitis
hepatitis
nephritis
renal dysfunction
thyroiditis
hypophysitis
pneumonitis
myocarditis
neuritis